Amgen: Carcinoma trials

The registry lists 18 Carcinoma studies with Amgen as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 4Phase 2 14Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)CompletedNCT02626000Phase 1Results posted
• Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck CancerTerminatedNCT01161498Phase 3Results posted
• AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With SunitinibCompletedNCT00853372Phase 2Results posted
• A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and NeckCompletedNCT00756444Phase 2Results posted
• Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00547157Phase 2Results posted
• Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck CancerCompletedNCT00500760Phase 2Results posted
• PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)CompletedNCT00446446Phase 2Results posted
• Safety Study of AMG 228 to Treat Solid TumorsTerminatedNCT02437916Phase 1
• Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular CarcinomaWithdrawnNCT02227914Phase 1/2
• AMG 172 First in Human Study in Patients With Kidney CancerCompletedNCT01497821Phase 1
• A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular CancerCompletedNCT00872014Phase 2
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal CarcinomaCompletedNCT00752570Phase 2
• AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With SorafenibCompletedNCT00467025Phase 2
• Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2CompletedNCT00425035Phase 2
• A Phase II Study to Treat Subjects With Advanced Renal Cell CarcinomaCompletedNCT00422019Phase 2
• Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinomaCompletedNCT00111774Phase 2
• T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma PatientsTerminatedNCT00057382Phase 2/3
• Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.Status unknownNCT00043433Phase 2